8 results on '"Lara, Abigail"'
Search Results
2. Contributors
- Author
-
Adams, Lewis, primary, Alberg, Anthony J., additional, Albert, Richard K., additional, Albertine, Kurt H., additional, Anantham, Devanand, additional, Arenberg, Douglas, additional, Ayas, Najib T., additional, Balkissoon, Ronald C., additional, Balmes, John R., additional, Bapoje, Srinivas R., additional, Barberà, Joan Albert, additional, Barnes, Peter J., additional, Baroody, Fuad M., additional, Becklake, Margaret R., additional, Benditt, Joshua O., additional, Benowitz, Neal L., additional, Blanc, Paul D., additional, Boucher, Richard C., additional, Bove, Alfred A., additional, Brambilla, Elisabeth, additional, Broaddus, V. Courtney, additional, Brown, Kevin K., additional, Brunetta, Paul G., additional, Cadranel, Jacques, additional, Carbone, David P., additional, Celli, Bartolome R., additional, Chan, Edward D., additional, Chan-Yeung, Moira, additional, Channick, Richard N., additional, Chastre, Jean, additional, Chung, Kian Fan, additional, Cirino-Marcano, Maria, additional, Coleman, R. Edward, additional, Collard, Harold R., additional, Cool, Carlyne D., additional, Cordier, Jean-François, additional, Corte, Tamera J., additional, Cottin, Vincent, additional, Cowie, Robert L., additional, Crapo, Robert O., additional, Crothers, Kristina, additional, Daley, Charles L., additional, Davies, Scott F., additional, De Marco, Teresa, additional, Sorbo, Lorenzo Del, additional, Downey, Gregory P., additional, Drake, Wonder, additional, du Bois, Roland M., additional, Duffin, James, additional, Effros, Richard M., additional, Eisner, Mark D., additional, Elicker, Brett M., additional, Ernst, Armin, additional, Fedullo, Peter F., additional, Fenton, Matthew J., additional, Fertel, Daniel, additional, Folkesson, Hans G., additional, Folz, Rodney J., additional, Fontenot, Andrew P., additional, Garcia, Joe G.N., additional, Gebhart, Gerald F., additional, Giordano, Thomas J., additional, Girard, Nicolas, additional, Gladwin, Mark T., additional, Gotway, Michael B., additional, Greenberg, James M., additional, Griffith, David E., additional, Groshong, Stephen, additional, Hegewald, Matthew J., additional, Henson, Peter M., additional, Hill, Nicholas S., additional, Hopewell, Philip C., additional, Huang, Laurence, additional, Inoue, Yoshikazu, additional, Iseman, Michael D., additional, Jackson, James E., additional, Jacobson, Jeffrey R., additional, Jett, James R., additional, Karnak, Demet, additional, Kato-Maeda, Midori, additional, Kavuru, Mani S., additional, King, Talmadge E., additional, Knowles, Michael R., additional, Knox, Kenneth S., additional, Kotloff, Robert M., additional, Kraft, Monica, additional, Kupeli, Elif, additional, Lapinsky, Stephen E., additional, Lara, Abigail R., additional, Lazarus, Stephen C., additional, Eun-Hyung Lee, F., additional, Lee, Warren L., additional, Lee, Y.C. Gary, additional, Lee-Chiong, Teofilo, additional, Lewis, James F., additional, Light, Richard W., additional, Limper, Andrew H., additional, Loddenkemper, Robert, additional, Luce, John M., additional, Lugogo, Njira, additional, Luks, Andrew M., additional, Luyt, Charles-Edouard, additional, Machado, Roberto F., additional, MacIntyre, Neil R., additional, Maier, Lisa A., additional, Maldonado, Fabien, additional, Malo, Jean-Luc, additional, Martin, Erica L., additional, Martin, Thomas R., additional, Mason, Robert J., additional, Massion, Pierre P., additional, Matthay, Michael A., additional, Matthay, Richard A., additional, Mayer, Annyce S., additional, McCarthy, James, additional, McCool, F. Dennis, additional, McCormack, Francis X., additional, McGlothlin, Dana, additional, Mehta, Atul C., additional, Menéndez, Rosario, additional, Morris, Alison, additional, Morris, Timothy A., additional, Morrison, Lake D., additional, Moss, Marc, additional, Murray, Jill, additional, Murray, John F., additional, Myers, Jeffrey L., additional, Nadel, Jay A., additional, Nakata, Koh, additional, Neuman, Thomas S., additional, Newman, Lee S., additional, Noble, Paul W., additional, Noppen, Marc, additional, Nutman, Thomas B., additional, O’Riordan, Thomas G., additional, Pack, Allan I., additional, Paré, Peter D., additional, Park, David R., additional, Patz, Edward F., additional, Phillipson, Eliot A., additional, Pickens, Allan, additional, Pien, Grace W., additional, Powell, Frank L., additional, Pritt, Bobbi S., additional, Que, Loretta G., additional, Ranieri, V. Marco, additional, Reilly, John J., additional, Rennard, Stephen I., additional, Reynolds, Susan D., additional, Riches, David W.H., additional, Rizk, Norman W., additional, Robinson, Bruce W.S., additional, Rodriguez-Roisin, Roberto, additional, Rose, Cecile S., additional, Roussos, Charis, additional, Routes, John M., additional, Rubin, Lewis J., additional, Samet, Jonathan M., additional, Sandrock, Christian, additional, Sarosi, George A., additional, Sawyer, Richard T., additional, Schmidt, Gregory A., additional, Schoene, Robert B., additional, Schraufnagel, Dean E., additional, Schwartz, David A., additional, Schwartzstein, Richard M., additional, Schwarz, Marvin I., additional, Selman, Moises, additional, Shannon, John M., additional, Shapiro, Steven D., additional, Shepherd, Kenneth E., additional, Shovlin, Claire L., additional, Sietsema, Kathy E., additional, Silvestri, Gerard A., additional, Simonian, Philip L., additional, Slutsky, Arthur S., additional, Smaldone, Gerald C., additional, Sullivan, Eugene J., additional, Swenson, Erik R., additional, Togias, Alkis, additional, Torres, Antoni, additional, Trapnell, Bruce C., additional, Treanor, John, additional, Tuder, Rubin M., additional, Tzelepis, George E., additional, Vallières, Eric, additional, Wagner, Peter D., additional, Weiss, Scott T., additional, Wells, Athol U., additional, West, John B., additional, White, Douglas B., additional, Widdicombe, John G., additional, Wiener-Kronish, Jeanine P., additional, Wunderink, Richard, additional, Yankaskas, James R., additional, Yao, Joseph D.C., additional, Zakynthinos, Spyros G., additional, Zimmerman, Leslie, additional, and ZuWallack, Richard L., additional
- Published
- 2010
- Full Text
- View/download PDF
3. Contributors
- Author
-
Anderson, Erica, primary, Azrak, Iyad, additional, Bajwa, Nadia, additional, Braver, Yvonne, additional, Einstein, David, additional, Falcone, Tatiana, additional, Frost, Natasha, additional, Gubanich, Paul, additional, Helton, Thomas, additional, Hoogwerf, Byron, additional, Jacob, Jesse, additional, Kirsch, Jacobo, additional, Lara, Abigail, additional, Lascano, Martin, additional, Mani, Aruna, additional, Marrero, Frank, additional, McDonald, Jonelle, additional, Mehta, Neil, additional, Mekhail, Tarek, additional, Moffa, Donald, additional, Newton, Marisha, additional, Nielsen, Craig, additional, Protain, Alison, additional, Rolston, David, additional, Russman, Andrew, additional, Shepard, Dale, additional, Shivadas, Anita, additional, Sidhu, Navneet, additional, Sood, Apra, additional, and Tiu, Ramon, additional
- Published
- 2008
- Full Text
- View/download PDF
4. Production of native recombinant proteins using a novel split intein affinity technology.
- Author
-
Clifford R, Lindman S, Zhu J, Luo E, Delmar J, Tao Y, Ren K, Lara A, Cayatte C, McTamney P, O'Connor E, and Öhman J
- Subjects
- Humans, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Recombinant Proteins genetics, Recombinant Proteins isolation & purification, Spike Glycoprotein, Coronavirus metabolism, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus isolation & purification, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Recombinant Fusion Proteins isolation & purification, SARS-CoV-2 genetics, SARS-CoV-2 chemistry, Interleukin-1beta metabolism, Interleukin-1beta genetics, Inteins, Chromatography, Affinity methods
- Abstract
Affinity tags are frequently engineered into recombinant proteins to facilitate purification. Although this technique is powerful, removal of the tag is desired because the tag can interfere with biological activity and can potentially increase the immunogenicity of therapeutic proteins. Tag removal is complex, as it requires adding expensive protease enzymes. To overcome this limitation, split intein based affinity purification systems have been developed in which a C
C -intein tag is engineered into a protein of interest for binding to a NC -intein peptide ligand fixed to a chromatographic support. Tag removal in these systems is achieved by creating an active intein-complex during protein capture, which triggers a precise self-cleavage reaction. In this work, we show applications of a new split intein system, Cytiva™ ProteinSelect™. One advantage of the new system is that the NC -intein ligand can be robustly produced and conjugated to large volumes of resin for production of gram scale proteins. SARS-CoV-2 spike protein receptor binding domain and a Bispecific T Cell Engager in this work were successfully captured on the affinity resin and scaled 10-fold. Another advantage of this system is the ability to sanitize the resin with sodium hydroxide without loosing the 10-20 g/L binding capacity. Binding studies with IL-1b and IFNAR-1 ECD showed that the resin can be regenerated and sanitized for up to 50 cycles without loosing binding capacity. Additionally, after several cycles of sanitization, binding capacity was retained for the SARS-CoV-2 spike protein receptor binding domain and a Bispecific T Cell Engager. As with other split intein systems, optimization was needed to achieve ideal expression and recovery. The N-terminal amino acid sequence of the protein of interest required engineering to enable the cleavage reaction. Additionally, ensuring the stability of the CC -intein tag was important to prevent premature cleavage or truncation. Controlling the hold time of the expression product and the prevention of protease activity prior to purification was needed. These results demonstrate the feasibility of the Cytiva™ ProteinSelect™ system to be used in academic and industrial research and development laboratories for the purification of novel proteins expressed in either bacterial or mammalian systems., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Johan Ohman has patent #WO2021099607A1 licensed to CYTIVA BIOPROCESS R&D AB. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
5. Increased lymphatic vessel length is associated with the fibroblast reticulum and disease severity in usual interstitial pneumonia and nonspecific interstitial pneumonia.
- Author
-
Lara AR, Cosgrove GP, Janssen WJ, Huie TJ, Burnham EL, Heinz DE, Curran-Everett D, Sahin H, Schwarz MI, Cool CD, Groshong SD, Geraci MW, Tuder RM, Hyde DM, and Henson PM
- Subjects
- Aged, Biopsy, Case-Control Studies, Collagen metabolism, Female, Humans, Lung diagnostic imaging, Lung metabolism, Lung pathology, Lung Diseases, Interstitial metabolism, Lymphangiogenesis physiology, Lymphatic Vessels physiopathology, Male, Middle Aged, Radiography, Vascular Endothelial Growth Factor A blood, Vascular Endothelial Growth Factor C blood, Vascular Endothelial Growth Factor D blood, Collagen ultrastructure, Fibroblasts pathology, Lung Diseases, Interstitial classification, Lung Diseases, Interstitial pathology, Lymphatic Vessels pathology, Severity of Illness Index
- Abstract
Background: Lymphangiogenesis responds to tissue injury as a key component of normal wound healing. The development of fibrosis in the idiopathic interstitial pneumonias may result from abnormal wound healing in response to injury. We hypothesize that increased lymphatic vessel (LV) length, a marker of lymphangiogenesis, is associated with parenchymal components of the fibroblast reticulum (organizing collagen, fibrotic collagen, and fibroblast foci), and its extent correlates with disease severity., Methods: We assessed stereologically the parenchymal structure of fibrotic lungs and its associated lymphatic network, which was highlighted immunohistochemically in age-matched samples of usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP) with FVC < 80%, COPD with a Global Initiative for Obstructive Lung Disease stage 0, and normal control lungs., Results: LV length density, as opposed to vessel volume density, was found to be associated with organizing and fibrotic collagen density (P < .0001). Length density of LVs and the volume density of organizing and fibrotic collagen were significantly associated with severity of both % FVC (P < .001) and diffusing capacity of the lung for carbon monoxide (P < .001)., Conclusions: Severity of disease in UIP and NSIP is associated with increased LV length and is strongly associated with components of the fibroblast reticulum, namely organizing and fibrotic collagen, which supports a pathogenic role of LVs in these two diseases. Furthermore, the absence of definable differences between UIP and NSIP suggests that LVs are a unifying mechanism for the development of fibrosis in these fibrotic lung diseases.
- Published
- 2012
- Full Text
- View/download PDF
6. Diffuse alveolar hemorrhage.
- Author
-
Lara AR and Schwarz MI
- Subjects
- Adrenal Cortex Hormones therapeutic use, Biopsy, Bronchoalveolar Lavage, Hemorrhage pathology, Humans, Immunosuppressive Agents therapeutic use, Lung Diseases pathology, Plasmapheresis, Pulmonary Alveoli pathology, Hemorrhage etiology, Hemorrhage therapy, Lung Diseases etiology, Lung Diseases therapy
- Abstract
Diffuse alveolar hemorrhage (DAH) is often a catastrophic clinical syndrome causing respiratory failure. Recognition of DAH often requires BAL as symptoms are nonspecific, hemoptysis is absent in up to one-third of patients, and radiographic imaging is also nonspecific and similar to other acute alveolar filling processes. Once the diagnosis is established, the underlying cause must be established in order to initiate treatment. This review discusses the diagnosis of the underlying histologies and the clinical entities that are responsible for DAH as well as treatment options.
- Published
- 2010
- Full Text
- View/download PDF
7. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation.
- Author
-
Calfee CS, Budev MM, Matthay MA, Church G, Brady S, Uchida T, Ishizaka A, Lara A, Ranes JL, deCamp MM, and Arroliga AC
- Subjects
- Adult, Biomarkers blood, Cohort Studies, Female, Humans, Intensive Care Units, Length of Stay, Linear Models, Lung Transplantation adverse effects, Male, Middle Aged, Pneumonia blood, Pneumonia etiology, Predictive Value of Tests, Prognosis, Prospective Studies, Receptor for Advanced Glycation End Products, Treatment Outcome, Lung Transplantation physiology, Receptors, Immunologic blood, Respiration, Artificial
- Abstract
Background: Primary graft dysfunction, formerly termed reperfusion pulmonary edema, is the leading cause of short-term complications after lung transplantation. New evidence shows that alveolar type I epithelial cells play an active role in alveolar fluid transport and are therefore presumed to be critical in the absorption of pulmonary edema. We tested the potential relevance of a novel marker of alveolar type I cell injury, the receptor for advanced glycation end-products (RAGE), to short-term outcomes of lung transplantation., Methods: The study was a prospective, observational cohort study of 20 patients undergoing single lung, bilateral lung or combined heart-lung transplantation. Plasma biomarkers were measured 4 hours after allograft reperfusion., Results: Higher plasma RAGE levels were associated with a longer duration of mechanical ventilation and longer intensive care unit length of stay, in contrast to markers of alveolar type II cell injury, endothelial injury and acute inflammation. Specifically, for every doubling in plasma RAGE levels, the duration of mechanical ventilation increased on average by 26 hours, adjusting for ischemia time (95% confidence interval [CI] 7.4 to 44.7 hours, p = 0.01). Likewise, for every doubling of plasma RAGE levels, intensive care unit length of stay increased on average by 1.8 days, again adjusting for ischemia time (95% CI 0.13 to 3.45 days p = 0.04). In contrast, the clinical diagnosis of primary graft dysfunction was not as predictive of these short-term outcomes., Conclusions: Higher levels of plasma RAGE measured shortly after reperfusion predicted poor short-term outcomes from lung transplantation. Elevated plasma RAGE levels may have both pathogenetic and prognostic value in patients after lung transplantation.
- Published
- 2007
- Full Text
- View/download PDF
8. Ischemic mitral regurgitation: impact of the left ventricle and mitral valve in patients with left ventricular systolic dysfunction.
- Author
-
Srichai MB, Grimm RA, Stillman AE, Gillinov AM, Rodriguez LL, Lieber ML, Lara A, Weaver JA, McCarthy PM, and White RD
- Subjects
- Aged, Cicatrix, Coronary Artery Disease complications, Echocardiography, Female, Heart Ventricles, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Mitral Valve, Mitral Valve Insufficiency diagnosis, Mitral Valve Insufficiency etiology, Myocardial Ischemia diagnosis, Myocardial Ischemia etiology, Retrospective Studies, Ventricular Dysfunction, Left diagnosis, Ventricular Dysfunction, Left etiology, Mitral Valve Insufficiency physiopathology, Myocardial Ischemia physiopathology, Ventricular Dysfunction, Left physiopathology
- Abstract
Background: Mitral regurgitation (MR) is a common complication of ischemic heart disease, and its presence portends adverse outcomes. As the exact mechanisms of ischemic MR are not well defined, we characterized left ventricular global geometry, regional function, and regional myocardial scarring, in addition to mitral valve apparatus geometry, using magnetic resonance imaging (MRI) of ischemic heart disease patients with left ventricular dysfunction and varying degrees of ischemic MR., Methods: Sixty patients with varying degrees of MR (none, mild, moderate, and severe) determined by echocardiography and referred for MRI assessment of ischemic heart disease were included. Left ventricular geometric, functional, and scar measurements in addition to mitral valve geometric measurements were evaluated., Results: Clinical characteristics found to be significant predictors of degree of MR included severity of coronary artery disease (p < 0.05), completeness of myocardial perfusion (p < 0.005), and average systolic blood pressure (p < 0.05). Mitral systolic tenting area (p < 0.0001) in a statistical model with scarring of the anterior-lateral region (p < 0.05) proved to be the most powerful predictor of MR severity (r2 = 0.31). Mitral annular dilatation in the anterior-posterior direction (p < 0.0001) and diminished LV systolic function (p < 0.005) were important determinants of mitral systolic tenting area (r2 = 0.57)., Conclusions: Mitral tenting in combination with regional left ventricular myocardial scarring are important mechanisms to the development of ischemic MR. Surgical annuloplasty addresses mitral tenting, but has little impact on the effect of regional scarring. Moderate-to-severe ischemic MR develops in patients with regional scarring of the anterior-lateral and inferior-posterior regions, and new surgical developments should take this into account.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.